FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1984698756> ?p ?o ?g. }

• W1984698756 endingPage "1888" @default.
• W1984698756 startingPage "1882" @default.
• W1984698756 abstract "HomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 20, No. 8Retinoids and Arterial Smooth Muscle Cells Free AccessOtherPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessOtherPDF/EPUBRetinoids and Arterial Smooth Muscle Cells Pascal Neuville, Marie-Luce Bochaton-Piallat and Giulio Gabbiani Pascal NeuvillePascal Neuville From the Department of Pathology, University of Geneva-CMU, Geneva, Switzerland. Search for more papers by this author , Marie-Luce Bochaton-PiallatMarie-Luce Bochaton-Piallat From the Department of Pathology, University of Geneva-CMU, Geneva, Switzerland. Search for more papers by this author and Giulio GabbianiGiulio Gabbiani From the Department of Pathology, University of Geneva-CMU, Geneva, Switzerland. Search for more papers by this author Originally published1 Aug 2000https://doi.org/10.1161/01.ATV.20.8.1882Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1882–1888is corrected byCorrectionRetinoic acid (RA), the active metabolite of vitamin A, is a crucial signaling molecule during vertebrate development and plays key roles in establishing cell lineages as well as in cell differentiation and proliferation.1 RA has been shown to influence the expression of many genes (see the Table) through interactions between RA receptors (RARs) and the RA response element (RARE) located in promoter regions.4243 RARs, transducers of the RA signal at the gene expression level, are members of the nuclear receptor superfamily. Essentially 2 subfamilies of nuclear receptor are known to function as RA-dependent transcription factors: the RARs and the retinoid X receptors (RXRs).44 These receptors, in the form of homodimers or heterodimers, recognize response elements located in the promoter regions of target genes. For each subfamily, 3 different genes (RAR-α, -β, and -γ; RXR-α, -β, and -γ) generate multiple isoforms with specific patterns of expression in both the embryo and adult, suggesting that they perform specific functions in the control of RA target genes.45 The uptake, transport, and metabolism of all-trans retinol is regulated by the cellular retinol-binding proteins (CRBP I and CRBP II), whereas the cellular RA-binding proteins (CRABP I and CRABP II) exert the same function for RA.1 Unlike RARs, retinoid-binding proteins modulate the effect of RA by regulating its intracellular level. Several lines of evidence indicate that CRBPs and CRABPs have distinct physiological roles. CRBPs provide the substrate for RA biosynthesis,46 whereas CRABPs are substrates for RA catabolism.47 Retinoids have not been extensively studied with regard to smooth muscle cell (SMC) biology. Their role in establishing SMC lineages has long been reported, but their influence on SMC function and their potential therapeutic use for vascular proliferative disorders are only starting to be appreciated. This review summarizes some of these recent advances.RA and SMC LineageRA has a teratogenic effect when applied during critical times of embryonic development.48 Both the lack of and excess RA may damage embryonic structures, including the cardiovascular apparatus.49 RA induces cardiac malformations,5051 sharing effects with neural crest ablation.52 The neural crest is a transient, ectodermal structure of the vertebrate embryo containing cells that develop into various lineages. The cardiac subset of neural crest cells participates in the formation of the media of large arteries5354 in combination with cells originating from the lateral mesoderm–derived mesenchyme.55 SMCs isolated from the thoracic aorta (derived from the neural crest) and abdominal aorta (derived from the mesoderm) of chick embryo and placed in culture differ morphologically: ectodermal cells have an epithelioid shape and grow in a monolayer, whereas mesodermal SMCs display the typical “hill-and-valley” growth pattern (see the section below on RA and SMC Biological Features).56 However, analysis of SMC differentiation markers (eg, α-SM actin, SM myosin, SM-22α, desmin, and calponin) in both cell types reveals similar expression levels.56A feature of neural crest–derived SMCs is their ability to be influenced by RA: on one hand, RA modulates differentiation of cardiac neural crest cells57 and on the other hand, neural crest–derived SMCs express RARs and binding proteins.5859 Recent studies on ductus arteriosus development have shed new light on the action of RA on neural crest–derived SMCs. The ductus arteriosus connects the pulmonary artery and the aorta in the fetal circulation; it arises from the left sixth aortic arch, which is essentially composed of neural crest–derived SMCs.54 At birth, closure of the ductus arteriosus is caused by the formation of an important intimal thickening followed by vessel constriction. SMCs of the ductus arteriosus exhibit an advanced differentiation of the contractile apparatus compared with those of adjacent large vessels.60 In particular, the SM myosin heavy-chain isoform found in vessels after birth (SM2) is already expressed in the media of the ductus arteriosus before birth.61 Colbert et al62 have generated transgenic mice carrying an RARE-lacZ transgene expressing β-galactosidase in response to endogenous RA. This reporter gene is specifically activated in SMCs of the ductus arteriosus during embryonic and neonatal development and is colocalized with SM2. Taken together, these results suggest that in the developing ductus arteriosus, RA acts as a signal promoting the differentiation of a subset of neural crest–derived SMCs.Other evidence suggesting interactions between RA and SMC lineage have arisen from studies on differentiation of embryonal carcinoma cells. Embryonal carcinoma cells can be induced to differentiate in vitro into a variety of cell types by treatment with different concentrations of RA.63 At low RA concentrations, they differentiate into fibroblast-like cells63 that express high levels of α-SM actin and SM myosin heavy chains and thus, resemble vascular SMCs.64 During RA-induced differentiation of P19 embryonal carcinoma cells, α-SM actin and CRBP are rapidly expressed.65 This CRBP induction occurs at RA concentrations that support embryonal carcinoma cell differentiation into SMCs. Increased levels of CRBP are also observed during F9 embryonal carcinoma cell differentiation induced by RA.66 Another cell line (9E11G), derived from RA-treated P19s, permanently expresses multiple characteristics of differentiated SMCs, including α-SM actin and SM myosin heavy-chain expression and functional responses to contractile agonists.67 More generally, it appears that induction of RA-responsive genes is a prerequisite for proper embryonal carcinoma cell differentiation, because a mutation affecting the RAR-α gene of the P19 mutant clone RAC65 blocks the induction of RA-responsive genes as well as RA-induced differentiation.6869 The fact that a number of genes expressed by differentiated SMCs appear after RA treatment argues in favor of the assumption that RA is a key molecule in SMC differentiation.RA and SMC Biological FeaturesHistorically, the first description of distinct SMC phenotypes has been achieved by the identification of contractile and synthetic cells, the first being typical of differentiated arteries and the second, typical of developing and/or pathological arteries.7071 Moreover, when arterial SMCs from adult animals are placed in culture, they switch their phenotype from contractile to synthetic. It is generally accepted that contractile and synthetic phenotypes can modulate from one to the other.7071 A further step in the establishment of SMC heterogeneity has been the characterization of spindle and epithelioid phenotypes.56727374 These SMC subtypes, studied mostly in the rat, have been isolated from different arterial locations or from the same location of animals at different ages, and they exhibit distinct features: (1) the classic “hill-and-valley” growth pattern for the spindle-shape phenotype that is usually obtained from the normal adult media and (2) growth as a contact-inhibited monolayer for the epithelioid phenotype that has been first and is usually isolated from the intimal thickening induced 15 days after endothelial injury (IT15).747576 It is accepted that spindle and epithelioid phenotypes permanently maintain their features in culture.757677 Moreover, when SMCs are cloned from the aortic media or from IT15 cells, both phenotypes are retrieved and again remain stable during culture conditions.78 However, the proportion of clones exhibiting these phenotypes differs according to their origin, with the media yielding a majority of spindle-shape clones and IT15 cells yielding a majority of epithelioid clones. Epithelioid SMCs, cultured as whole or clonal cell populations, show less-differentiated cytoskeletal features (eg, α-SM actin, SM myosin, and desmin expression), are able to grow in the absence of serum, and exhibit higher migratory activity compared with spindle-shape cells.7778 Taken together, these findings suggest that intimal thickening develops essentially from a subpopulation of medial SMCs exhibiting epithelioid features in vitro.In an attempt to identify proteins differentially expressed between different SMC phenotypes, we have observed that CRBP expression is restricted to rat aortic SMCs cultured from IT15 cells displaying an epithelioid phenotype and to epithelioid clones derived from either the normal media or IT15 cells.279 Thus, CRBP expression can be used as a marker of epithelioid cells in vitro. Moreover, CRBP is transiently expressed by a subset of SMCs during neointima formation. CRBP-positive cells proliferate at early stages and disappear, allegedly through apoptosis, at later stages of neointimal evolution,2 suggesting that a modulation of the retinoid content may be required for both processes. CRBP upregulation is a direct transcriptional effect of RA, mediated through binding of the RAR-α–RXR-α heterodimer to the RARE of the CRBP promoter.80 In SMCs, the pattern of expression of the 3 RAR and RXR genes has been studied.5 Five of the 6 receptors are expressed in rat SMCs in vitro, but in vivo, only RXR-γ is undetectable. The presence of these receptors indicates that SMCs can respond to RA.RA modulates various SMC features. It has been reported that RA either increases81 or decreases2582 SMC proliferation. This paradoxical effect has recently been clarified by Chen and Gardner83 : RA stimulates quiescent SMCs by increasing expression of cyclin D1, which is involved in cell entry into the G1 phase, whereas serum-stimulated cells are growth inhibited through a decrease in extracellular signal–regulated protein kinase activity. This property seems to be independent of SMC phenotype, because serum-stimulated epithelioid and spindle-shape SMCs are growth inhibited.28 The role of RA in SMC migration in vitro remains unclear. The plasminogen activator (PA) system and the matrix metalloproteinases (MMPs) are both involved in extracellular matrix (ECM) degradation, which is believed to mediate SMC migration. RA has been shown to reduce SMC migration, possibly by decreasing collagenase and stromelysin transcription, 2 MMPs induced by mechanical injury.84 However, we have observed that RA increases migration of both medial and IT15 SMCs, probably by stimulating tissue-type plasminogen activator (tPA) activity.28 tPA is the main PA involved in the proteolytic activities of SMCs in vitro, and the higher proteolytic activity of IT15 cells is mainly due to increased expression of tPA.29 Thus, the opposite effects of RA on SMC migration in vitro are likely due to its differential action on the PA system and MMPs (see the section below on RA and SMC Gene Expression). In addition to SMC proliferation and migration, RA may influence SMC differentiation, because α-SM actin expression can be enhanced or reduced,1028 and SMC phenotype, because RA induces the transition from the epithelioid shape to the spindle one.2The action of RA in vivo is less controversial. In the rat carotid injury model, RA decreases neointimal cellularity and ECM deposition, leading to a one-third increase in lumen diameter and area.288586 RA also induces favorable remodeling of the injured artery.8587 Medial area and cell number are unaffected, suggesting, among several possibilities, that in vivo RA specifically influences the SMCs prone to migrate, proliferate, and give rise to the neointima. As discussed above, this RA responsiveness may be correlated with a particular phenotypic and/or embryological origin.Because different SMC phenotypes are engaged in different genetic programs, it is of interest to investigate possible differential expression of the 5 receptors or of the isoforms corresponding to a given RAR subtype. To identify which RAR may have a differential effect on distinct SMC phenotypes, we tested RA agonists specific for each receptor. Among them, only RAR-α agonists were able to inhibit SMC proliferation in vitro and to reduce intimal thickening formation in vivo.28 Thus, RA may specifically influence the SMC phenotype responsible for formation of the neointima through an RAR-α–dependent signaling pathway. It has recently been reported that RAR-γ agonists inhibit in vitro SMC proliferation as well.82 These results suggest that RA may be potentially useful in regulating SMC differentiation, migration, and proliferation in vascular diseases involving neointima formation.It has been suggested that in some situations, the vascular healing process may involve adventitial fibroblasts in producing arterial remodeling and/or neointima formation.88 These fibroblasts modulate into myofibroblasts expressing α-SM actin and producing ECM components under transforming growth factor-β (TGF-β) stimulation.8990 We have observed that after induction of an open wound in the back skin of the rat, myofibroblasts start to express CRBP during the proliferation phase; CRBP expression persists until myofibroblasts disappear through apoptosis.91 These observations are compatible with the possibility that CRBP expression and RA modulation are common features of repair processes. Our results suggest that RA may be potentially useful in regulating SMC differentiation, migration, and proliferation in vascular diseases involving neointima formation.RA and SMC Gene ExpressionRA influences the expression of many genes, including those associated with cell growth and differentiation.43 It may activate the transcription of target genes or repress other genes by antagonizing the function of the activator protein-1 (AP-1) transcription factor.92 AP-1 is a heterodimer of c-fos and c-jun that binds to AP-1 consensus sequences and activates genes related to cell proliferation, migration, apoptosis, and ECM production.93 These 4 processes have been shown to play key roles in the progression of atherosclerosis and restenosis.9495 An impressive number of genes are positively or negatively regulated by RA (see the Table ). Most of them are in some way involved in the development of atherosclerotic lesions or in the formation of the arterial neointima. Thus, c-fos and c-jun are rapidly induced after arterial injury, leading to the formation of AP-1 and to the activation of AP-1–regulated genes,33 such as fibroblast growth factor-2, TGF-β1, c-myc, endothelin-1, stromelysin, collagenase, or the precursor of the MMP-1, pro–MMP-1.409697 RA can inhibit the expression of some of these genes, such as those for collagenase, stromelysin, and pro–MMP-1.324098 The RA-induced inhibition of MMPs is generally accompanied by an RA-mediated activation of genes encoding ECM components, such as fibronectin, laminin, and collagen type IV.99100 Thus, RA allegedly modifies the SMC genetic program to favor the formation of ECM, which may in turn decrease cell migration and maintain cell differentiation.101102 In relation to cardiovascular diseases, the action of RA as a negative regulator of AP-1–responsive genes may be considered beneficial. On the other hand, arterial injury results in an increase of platelet-derived growth factor (PDGF), PDGF receptors, and TGF-β194103 that are responsible for the induction of SMC migration and proliferation and that are also potential target genes for RA.104105 Moreover, some of the actions of RA are considered to be mediated or potentiated by induction of TGF-β1, and cross-talk between their signal transduction pathways is well established.106107 Thus, it appears that RA is also capable of enhancing the effects of atherogenic growth factors. These observations underline the complexity of the RA influence on SMCs and support the notion that the action of RA on SMC behavior, and probably on vascular diseases, largely depends on local environmental changes and on the pattern of genes expressed at a given time.Conclusions and PerspectivesAlthough it is well accepted that RA plays an important role in vascular development, the multifaceted activity of RA in arterial SMCs of adult animals is presently an emerging, though rapidly developing, topic. It is now well established that RA influences SMC replication and motility, and, through its pleiotropic action, RA may affect other processes involved in the pathogenesis of vascular diseases. Recent work points particularly to the possibility that RA affects SMC participation in such phenomena as restenosis and plaque formation.2885 The findings that RA can exert distinct actions on epithelioid versus spindle SMC phenotypes in culture and can reduce experimental intimal thickening in vivo are encouraging; however, further work is required to elucidate the mechanisms by which RA affects SMC function in vitro and in vivo. Nevertheless, one can confidently anticipate that the field of SMC modulation by RA in biological and pathological situation will develop importantly during the next several years.Göran Hansson kindly served as Guest Editor for this article. Table 1. Nonexhaustive List of Genes Regulated by RA and Involved in Different Aspects of Atherogenesis and RestenosisNameInvolvementCell Type StudiedLocation and Relationship to SMCsReference No.CRBPtRA synthesisRat aortic SMCsExperimental arterial lesions; mediates phenotypic modulation2CRABPtRA synthesisHuman fibroblastsNeural crest–derived SMCs3, 4RAR-αtRA signaling pathwayRat aortic SMCsRat aortic SMCs; mediates tRA action2, 5PPAR-γDimer with RXRRat and human SMCsNormal vessel and human arterial lesions; activation inhibits migration6, 7PPAR-αDimer with RXRHuman aortic SMCsHuman aortic SMCs; inhibits inflammatory response7, 8Ha-rasInduced by tRARat aortic SMCsHuman and rat transformed SMCs; maintenance of a dedifferentiated phenotype9Protein kinase CInduced by tRARat aortic SMCsNormal vessel and human arterial lesions; differentiation, proliferation10, 11TGF-βInduced by tRATumor cell linesNormal vessel and human arterial lesions; ECM accumulation12, 13IFN-γReduced by tRATumor cell linesHuman arterial lesions; multifunctional (proliferation, inflammation, apoptosis)14, 15iNOSInduced by tRARat aortic SMCsNormal vessel and human arterial lesions; multifunctional (inflammation, proliferation)16, 17PDGF-α receptorInduced by tRAF9 teratocarcinomaNormal vessel and human arterial lesions; initiation of atherogenesis signaling pathways18, 19Collagen IVInduced by tRAF9 teratocarcinomaHuman and experimental arterial lesions; ECM formation, phenotype modulation20, 21Laminin B1Induced by tRAF9 teratocarcinomaHuman and experimental arterial lesions; ECM formation, phenotype modulation20, 21ElastinInduced by tRAChick embryo SMCsDegraded in arterial diseases; loss of elasticity, interaction with lipids22, 23Connexin 43Induced by tRAF9 teratocarcinomaNormal vessel and human arterial lesions; phenotypic modulation24, 25ICAMInduced by tRATumor cell linesNormal vessel and human arterial lesions; contribution to inflammatory response26, 27tPAInduced by tRARat aortic SMCsExperimental arterial lesions; ECM degradation28, 29c-mycReduced by tRAF9 teratocarcinomaHuman arterial lesions; stimulates proliferation30, 31AP-1–responsive genesReduced by tRAFibroblastsExperimental arterial lesions; activation of genes involved in migration, proliferation, ECM production32, 33Apolipoprotein AReduced by tRAHepatocytesConstituent of HDLs; antiatherogenic properties34, 35FibronectinReduced by tRAKeratinocytesHuman and experimental arterial lesions; ECM formation, phenotype modulation21, 36ThrombospondinReduced by tRAKeratinocytesNormal vessel and human arterial lesions; proliferation and migration, ECM degradation36, 37VCAMReduced by tRAEndothelial cellsNormal vessel and human arterial lesions; mediates inflammatory response26, 38Tissue factorReduced by tRAMonocytesMacrophages of human arterial lesions; thrombus formation39Pro MMP-1Reduced by tRAHuman aortic SMCsHuman and experimental arterial lesions; ECM degradation40MMP-1Reduced by tRARabbit fibroblastsHuman and experimental arterial lesions; ECM degradation41MMP-3Reduced by tRAHeLa cellsHuman and experimental arterial lesions; ECM degradation32PPAR indicates peroxisome proliferator–activated receptor; IFN, interferon; iNOS, inducible nitric oxide synthase; ICAM, intercellular adhesion molecule; and VCAM, vascular cell adhesion molecule. See text for explanation of other abbreviations.This study was supported in part by the Swiss National Science Foundation (Grant No. 31.50568-97). We thank Sabine Josseron for typing the manuscript.FootnotesCorrespondence to Prof Giulio Gabbiani, Department of Pathology, University of Geneva-CMU, 1 Rue Michel Servet, 1211 Geneva 4/Switzerland. E-mail [email protected] (Arterioscler Thromb Vasc Biol. 2000;20:1882-1888.) References 1 Blomhoff R. Transport and metabolism of vitamin A. Nutr Rev.1994; 52:S13–S23.MedlineGoogle Scholar2 Neuville P, Geinoz A, Benzonana G, Redard M, Gabbiani F, Ropraz P, Gabbiani G. Cellular retinol-binding protein-1 is expressed by distinct subsets of rat arterial smooth muscle cells in vitro and in vivo. Am J Pathol.1997; 150:509–521.MedlineGoogle Scholar3 Astrom A, Pettersson U, Chambon P, Voorhees JJ. Retinoic acid induction of human cellular retinoic acid-binding protein-II gene transcription is mediated by retinoic acid receptor-retinoid X receptor heterodimers bound to one far upstream retinoic acid-responsive element with 5-base pair spacing. J Biol Chem.1994; 269:22334–22339.CrossrefMedlineGoogle Scholar4 Dencker L, Annerwall E, Busch C, Eriksson U. Localization of specific retinoid-binding sites and expression of cellular retinoic-acid-binding protein (CRABP) in the early mouse embryo. Development.1990; 110:343–353.CrossrefMedlineGoogle Scholar5 Miano JM, Topouzis S, Majesky MW, Olson EN. Retinoid receptor expression and all-trans retinoic acid–mediated growth inhibition in vascular smooth muscle cells. Circulation.1996; 93:1886–1895.CrossrefMedlineGoogle Scholar6 Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A.1998; 95:7614–7619.CrossrefMedlineGoogle Scholar7 Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res.1998; 83:1097–1103.CrossrefMedlineGoogle Scholar8 Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature.1998; 393:790–793.CrossrefMedlineGoogle Scholar9 Sadhu DN, Ramos K. Modulation by retinoic acid of spontaneous and benzo(a)pyrene-induced c-Ha-ras expression. Basic Life Sci.1993; 61:263–268.MedlineGoogle Scholar10 Haller H, Lindschau C, Quass P, Distler A, Luft FC. Differentiation of vascular smooth muscle cells and the regulation of protein kinase C-α. Circ Res.1995; 76:21–29.CrossrefMedlineGoogle Scholar11 McCarty MF. Up-regulation of intracellular signaling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion: the ‘PKC syndrome.’ Med Hypotheses.1996; 46:191–221.CrossrefMedlineGoogle Scholar12 Cohen PS, Letterio JJ, Gaetano C, Chan J, Matsumoto K, Sporn MB, Thiele CJ. Induction of transforming growth factor β1 and its receptors during all-trans-retinoic acid (RA) treatment of RA-responsive human neuroblastoma cell lines. Cancer Res.1995; 55:2380–2386.MedlineGoogle Scholar13 Bobik A, Agrotis A, Kanellakis P, Dilley R, Krushinsky A, Smirnov V, Tararak E, Condron M, Kostolias G. Distinct patterns of transforming growth factor-β isoform and receptor expression in human atherosclerotic lesions: colocalization implicates TGF-β in fibrofatty lesion development. Circulation.1999; 99:2883–2891.CrossrefMedlineGoogle Scholar14 Cippitelli M, Ye J, Viggiano V, Sica A, Ghosh P, Gulino A, Santoni A, Young HA. Retinoic acid-induced transcriptional modulation of the human interferon-γ promoter. J Biol Chem.1996; 271:26783–26793.CrossrefMedlineGoogle Scholar15 Vaddi K, Nicolini FA, Mehta P, Mehta JL. Increased secretion of tumor necrosis factor-α and interferon-γ by mononuclear leukocytes in patients with ischemic heart disease: relevance in superoxide anion generation. Circulation.1994; 90:694–699.CrossrefMedlineGoogle Scholar16 Hirokawa K, O’Shaughnessy KM, Ramrakha P, Wilkins MR. Inhibition of nitric oxide synthesis in vascular smooth muscle by retinoids. Br J Pharmacol.1994; 113:1448–1454.CrossrefMedlineGoogle Scholar17 Sirsjo A, Gidlof AC, Olsson A, Torma H, Ares M, Kleinert H, Forstermann U, Hansson GK. Retinoic acid inhibits nitric oxide synthase-2 expression through the retinoic acid receptor-α. Biochem Biophys Res Commun..2000; 270:846–851.CrossrefMedlineGoogle Scholar18 Afink GB, Nister M, Stassen BH, Joosten PH, Rademakers PJ, Bongcam-Rudloff E, Van Zoelen EJ, Mosselman S. Molecular cloning and functional characterization of the human platelet-derived growth factor α receptor gene promoter. Oncogene.1995; 10:1667–1672.MedlineGoogle Scholar19 Krettek A, Fager G, Jernberg P, Ostergren-Lunden G, Lustig F. Quantitation of platelet-derived growth factor receptors in human arterial smooth muscle cells in vitro. Arterioscler Thromb Vasc Biol.1997; 17:2395–2404.CrossrefMedlineGoogle Scholar20 Gudas LJ. Assays for expression of genes regulated by retinoic acid in murine teratocarcinoma cell lines. Methods Enzymol.1990; 190:131–140.CrossrefMedlineGoogle Scholar21 Thyberg J, Hulgardh-Nilsson A. Fibronectin and the basement membrane components laminin and collagen type IV influence the phenotypic properties of subcultured rat aortic smooth muscle cells differently. Cell Tissue Res.1994; 276:262–271.Google Scholar22 Robert L, Robert AM, Jacotot B. Elastin-elastase-atherosclerosis revisited. Atherosclerosis..1998; 140:281–295.CrossrefMedlineGoogle Scholar23 Hayashi A, Suzuki T, Tajima S. Modulations of elastin expression and cell proliferation by retinoids in cultured vascular smooth muscle cells. J Biochem (Tokyo).1995; 117:132–136.CrossrefMedlineGoogle Scholar24 Yeh HI, Lupu F, Dupont E, Severs NJ. Upregulation of connexin43 gap junctions between smooth muscle cells after balloon catheter injury in the rat carotid artery. Arterioscler Thromb Vasc Biol.1997; 17:3174–3184.CrossrefMedlineGoogle Scholar25 Clairmont A, Sies H. Evidence for a posttranscriptional effect of retinoic acid on connexin43 gene expression via the 3′-untranslated region. FEBS Lett.1997; 419:268–270.CrossrefMedlineGoogle Scholar26 Braun M, Pietsch P, Schror K, Baumann G, Felix SB. Cellular adhesion molecules on vascular smooth muscle cells. Cardiovasc Res.1999; 41:395–401.CrossrefMedlineGoogle Scholar27 Stratowa C, Audette M. Transcriptional regulation of the human intercellular adhesion molecule-1 gene: a short overview. Immunobiology.1995; 193:293–304.CrossrefMedlineGoogle Scholar28 Neuville P, Yan Z, Gidlof A, Pepper MS, Hansson GK, Gabbiani G, Sirsjo A. Retinoic acid regulates arterial smooth muscle cell proliferation and phenotypic features in vivo and in vitro through an RARα-dependent signaling pathway. Arterioscler Thromb Vasc Biol.1999; 19:1430–1436.CrossrefMedlineGoogle Scholar29 Bochaton-Piallat ML, Gabbiani G, Pepper MS. Plasminogen activator expression in rat arterial smooth muscle cells depends on their phenotype and is modulated by cytokines. Circ Res.1998; 82:1086–1093.CrossrefMedlineGoogle Scholar30 Golja AM, Rodino W, Panetta TF. Insight into atherosclerosis: a review of c-myc and the vascular smooth muscle cell. Cell Mol Biol Res.1995; 41:487–499.MedlineGoogle Scholar31 Griep AE, DeLuca HF. Decreased c-myc expression is an early event in retinoic acid-induced differentiation of F9 teratocarcinoma cells. Proc Natl Acad Sci U S A.1986; 83:5539–5543.CrossrefMedlineGoogle Scholar32 Nicholson RC, Mader S, Nagpal S, Leid M, Rochette-Egly C, Chambon P. Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. EMBO J.1990; 9:4443–4454.CrossrefMedlineGoogle Scholar33 Miano JM, Vlasic N, Tota RR, Stemerman MB. Smooth muscle cell immediate-early gene and growth factor activation follows vascular injury: a putative in vivo mechanism for autocrine growth. Arterioscler Thromb.1993; 13:211–219.CrossrefMedlineGoogle Scholar34 Sirtori CR, Calabresi L, Franceschini G. Recombinant apolipoproteins for the treatment of vascular diseases. Atherosclerosis.1999; 142:29–40.CrossrefMedlineGoogle Scholar35" @default.
• W1984698756 created "2016-06-24" @default.
• W1984698756 creator A5042174239 @default.
• W1984698756 creator A5056954886 @default.
• W1984698756 creator A5091042751 @default.
• W1984698756 date "2000-08-01" @default.
• W1984698756 modified "2023-10-16" @default.
• W1984698756 title "Retinoids and Arterial Smooth Muscle Cells" @default.
• W1984698756 cites W1567127662 @default.
• W1984698756 cites W1581075759 @default.
• W1984698756 cites W168098503 @default.
• W1984698756 cites W1835484652 @default.
• W1984698756 cites W1888616915 @default.
• W1984698756 cites W1916873700 @default.
• W1984698756 cites W1944595096 @default.
• W1984698756 cites W1954329710 @default.
• W1984698756 cites W1963881127 @default.
• W1984698756 cites W1969050011 @default.
• W1984698756 cites W1969079241 @default.
• W1984698756 cites W1970096907 @default.
• W1984698756 cites W1971155327 @default.
• W1984698756 cites W1971624992 @default.
• W1984698756 cites W1978963848 @default.
• W1984698756 cites W1979642590 @default.
• W1984698756 cites W1981990420 @default.
• W1984698756 cites W1998681781 @default.
• W1984698756 cites W2002566107 @default.
• W1984698756 cites W2003262612 @default.
• W1984698756 cites W2004044470 @default.
• W1984698756 cites W2006781499 @default.
• W1984698756 cites W2008006860 @default.
• W1984698756 cites W2015642624 @default.
• W1984698756 cites W2017160584 @default.
• W1984698756 cites W2021758696 @default.
• W1984698756 cites W2023981393 @default.
• W1984698756 cites W2025631499 @default.
• W1984698756 cites W2025937842 @default.
• W1984698756 cites W2026266301 @default.
• W1984698756 cites W2026578815 @default.
• W1984698756 cites W2026819360 @default.
• W1984698756 cites W2028212823 @default.
• W1984698756 cites W2031389321 @default.
• W1984698756 cites W2032361352 @default.
• W1984698756 cites W2035150988 @default.
• W1984698756 cites W2036224418 @default.
• W1984698756 cites W2036329770 @default.
• W1984698756 cites W2044976483 @default.
• W1984698756 cites W2048973684 @default.
• W1984698756 cites W2055523415 @default.
• W1984698756 cites W2066220906 @default.
• W1984698756 cites W2070196825 @default.
• W1984698756 cites W2071904183 @default.
• W1984698756 cites W2073516062 @default.
• W1984698756 cites W2075421725 @default.
• W1984698756 cites W2075703553 @default.
• W1984698756 cites W2076150009 @default.
• W1984698756 cites W2079906620 @default.
• W1984698756 cites W2087674175 @default.
• W1984698756 cites W2089389307 @default.
• W1984698756 cites W2097433480 @default.
• W1984698756 cites W2125414597 @default.
• W1984698756 cites W2133464116 @default.
• W1984698756 cites W2150905382 @default.
• W1984698756 cites W2150950460 @default.
• W1984698756 cites W2153467120 @default.
• W1984698756 cites W2156624598 @default.
• W1984698756 cites W2158403633 @default.
• W1984698756 cites W2419024403 @default.
• W1984698756 cites W2428968655 @default.
• W1984698756 cites W3135921402 @default.
• W1984698756 cites W52940050 @default.
• W1984698756 doi "https://doi.org/10.1161/01.atv.20.8.1882" @default.
• W1984698756 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10938007" @default.
• W1984698756 hasPublicationYear "2000" @default.
• W1984698756 type Work @default.
• W1984698756 sameAs 1984698756 @default.
• W1984698756 citedByCount "12" @default.
• W1984698756 countsByYear W19846987562012 @default.
• W1984698756 countsByYear W19846987562013 @default.
• W1984698756 countsByYear W19846987562015 @default.
• W1984698756 countsByYear W19846987562022 @default.
• W1984698756 crossrefType "journal-article" @default.
• W1984698756 hasAuthorship W1984698756A5042174239 @default.
• W1984698756 hasAuthorship W1984698756A5056954886 @default.
• W1984698756 hasAuthorship W1984698756A5091042751 @default.
• W1984698756 hasBestOaLocation W19846987561 @default.
• W1984698756 hasConcept C126322002 @default.
• W1984698756 hasConcept C185592680 @default.
• W1984698756 hasConcept C71924100 @default.
• W1984698756 hasConceptScore W1984698756C126322002 @default.
• W1984698756 hasConceptScore W1984698756C185592680 @default.
• W1984698756 hasConceptScore W1984698756C71924100 @default.
• W1984698756 hasIssue "8" @default.
• W1984698756 hasLocation W19846987561 @default.
• W1984698756 hasLocation W19846987562 @default.
• W1984698756 hasLocation W19846987563 @default.
• W1984698756 hasOpenAccess W1984698756 @default.
• W1984698756 hasPrimaryLocation W19846987561 @default.

• next